ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1061

Generation of Myeloid-Derived Suppressor Cells in Vitro From Murine Bone Marrow Precursors

Julia Kurko1, Beata Tryniszewska1, Tibor A. Rauch1, Colt Egelston2, Tibor T. Glant1 and Katalin Mikecz1, 1Orthopedic Surgery, Rush University Medical Center, Chicago, IL, 2Immunology, Rush University Medical Center, Chicago, IL

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Animal models, Bone marrow, neutrophils and rheumatoid arthritis (RA), T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Innate Immunity and Rheumatic Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Myeloid-derived suppressor cells (MDSCs) are innate immune cells that expand under pathological conditions (such as cancer and autoimmune diseases) in response to local growth factors or cytokines. MDSCs are a heterogeneous population of immature myeloid lineage (monocyte-like and granulocyte-like) cells with immunosuppressive ability. These cells have the potential to down-regulate autoreactive T cell responses in autoimmune diseases such as rheumatoid arthritis (RA). Using proteoglycan (PG)-induced arthritis (PGIA), a mouse model of RA, we previously reported that MDSCs are present in synovial fluid (SF) of the arthritic joints of mice and suppress antigen-specific T cell proliferation. As the number of cells that can be collected from murine SF is limited and SF MDSCs do not expand in culture, we sought an alternative source for generating greater quantities of MDSCs for potential therapeutic intervention (via cell transfer) in PGIA.

Methods: Bone marrow (BM) cells were isolated from naïve BALB/c mice and cultured in the presence of recombinant murine granulocyte macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF) and interleukin-6 (IL-6) for up to 7 days. After harvest, the phenotype of cells was evaluated by flow cytometry. Their suppressive function towards PG-specific T cells was tested by co-culture with PG-loaded BM-derived dendritic cells (DCs) and T cells from naïve PG-specific T cell receptor transgenic (PG-TCR-Tg) mice. The mechanisms of MDSC-mediated suppression were investigated using inhibitors of MDSC-produced effector molecules including arginase-1, inducible nitric oxide (NO) synthase (iNOS), and reactive oxygen species. Expression of MDSC effector molecules was analyzed by RT-PCR and Western blot.

Results: Similar to SF MDSCs, BM-derived MDSCs expressed the common myeloid marker CD11b. However, unlike SF MDSCs, BM MDSCs contained a smaller population of Ly6G positive (granulocyte-like) cells, and the majority of them expressed both Ly6G and the monocytoid cell surface marker Ly6C. Upon co-culture with PG-TCR-Tg T cells in the presence of PG-loaded DCs, BM MDSCs profoundly inhibited the proliferation of T cells, thereby confirming their suppressor activity. BM cells grown with GM-CSF, G-CSF, and IL-6 for only 3 days already showed potent suppressive effect on T cell proliferation. Despite expression of Ly6C by most BM MDSCs, these cells retained their suppressor activity after depletion of the Ly6C positive population. Experiments with inhibitors of MDSC effector molecules revealed that the primary mechanism of suppression of T cell proliferation was via NO release. Indeed, iNOS expression in BM MDSCs was found elevated at both mRNA and protein levels. 

Conclusion: We developed an in vitro culture method of generating large quantities of immunosupressive murine MDSCs. Characterization of the phenotype, gene expression, suppressor activity of BM-derived MDSCs revealed that these cells are similar to SF MDSCs, but are dominated by a less mature (double Ly6C/Ly6G positive) population. BM-derived MDSCs appear to be suitable for in vivo cell transfer experiments.


Disclosure:

J. Kurko,
None;

B. Tryniszewska,
None;

T. A. Rauch,
None;

C. Egelston,
None;

T. T. Glant,
None;

K. Mikecz,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/generation-of-myeloid-derived-suppressor-cells-in-vitro-from-murine-bone-marrow-precursors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology